- Evonik’s full-year adjusted EBITDA forecast for 2025 is EU1.9 billion, missing the previous estimate of EU1.96 billion.
- The company had initially projected a range from EU2 billion to EU2.3 billion.
- Preliminary results for the third quarter indicate an adjusted EBITDA between EU420 million and EU460 million.
- Estimated sales for the third quarter are approximately EU3.4 billion.
- Evonik had anticipated a slight economic recovery in the second half of 2025, which has not occurred.
- Customers are exhibiting cautious behavior across all segments and most end markets.
- Evonik will release the final third-quarter figures on November 4, 2025.
- Among analysts, there are 7 buy ratings, 8 holds, and 2 sells for Evonik.
Evonik Industries on Smartkarma
Evonik Industries has caught the attention of analysts on Smartkarma, with Baptista Research initiating coverage on the company. Their report titled “Evonik Industries: Initiation of Coverage- Will Methionine Market Tightness Trigger a Massive Upside Surprise?” delves into the performance of Evonik Industries AG, a global leader in specialty chemicals, in the first quarter of 2025. The company saw a substantial year-over-year increase in EBITDA and free cash flow, exceeding the prior year’s figures by over 50%. Despite a challenging macroeconomic backdrop, Evonik maintained its full-year guidance, driven by robust results in its Specialty Additives and Nutrition & Care segments.
A look at Evonik Industries Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Evonik Industries AG, a company specializing in manufacturing specialty chemicals, is drawing attention from investors with its strong performance in key areas. According to Smartkarma’s Smart Scores, Evonik Industries is rated highly for its dividend and value, receiving scores of 5 and 4 respectively. This indicates that the company is providing good returns to its investors and is considered valuable in the market.
While Evonik Industries shows promising strengths in dividend and value, its growth, resilience, and momentum scores are moderate, indicating room for improvement in these areas. With its focus on consumer goods, animal nutrition, and pharmaceuticals, Evonik Industries continues to be a solid player in the industry, appealing to investors seeking stable returns over the long term.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
